Search results - 3 results
Prevention of Cervical Cancer: Guideline of the DGGG and the DKG (S3 Level, AWMF Register Number 015/027OL, December 2017)- Part 1 with Introduction, Screening and the Pathology of Cervical Dysplasia.
this short summary presents the pathological basis and considers various questions related to screening for cervical cancer. As also reported in earlier reviews, the meta-analysis by Kleijnen Systematic ...
Clinical and Analytical Evaluation of the Anyplex II HPV HR Detection Assay within the VALGENT-3 Framework.
consistently showed excellent clinical performance and can be considered validated for primary cervical cancer screening. Health Topics: Quality of healthcare Cancer Qualité des soins de santé Kwaliteit van de ...
Clinical Evaluation of INNO-LiPA HPV Genotyping II Assay Using the VALGENT Framework.
assessment, we considered it as high-risk (hr) HPV positive when at least one of the following HPV types was present: HPV16, HPV18, HPV31, HPV33, HPV35, HPV39, HPV45, HPV51, HPV52, HPV56, HPV58, HPV59, and ...